Biotech/Life Science Conference to Bring Pharmaceutical Companies and Investors Together, Opportunity to Seek Funding for New Mesothelioma and Cancer Treatments
The Council for Entrepreneurial Development (CED) is once again hosting the Biotech/Life Science Conference in North Carolina where early-stage, small, drug-development companies get an opportunity to network with some of the pharmaceutical giants in the industry. GlaxoSmithKline, Merck, Pfizer and AstraZeneca, as well as many other biotech heavyweights, will meet one-on-one with small companies vying for much needed investment capital to bring their vision of innovative drugs to market. Funding for groundbreaking medical research is critical for finding a cure or new treatments for incurable diseases such as mesothelioma, diabetes and HIV/AIDs.
Mesothelioma, an asbestos-caused cancer, is both incurable and deadly. Close to 3,000 Americans are diagnosed with the disease each year, and the majority of them face a grim prognosis of 4-18 months survival. The disease is aggressive, and traditional mesothelioma treatments have been unable to prevent the cancer from metastasizing, or spreading, to other organs in the body. Researchers in the area of genetics and biotechnology are making advances, but continued studies and trials are needed to get the breakthrough needed to bring new treatments to the patients.
Touted as the “premier life science event of the Southeast,” the 20th annual CED conference offers a full agenda including partner meetings, panel discussions and keynote speakers. The speakers will cover key topics such as personalized medicine and health care reform, touching on the topics that may change the way healthcare is delivered in the future.
There is a move in the medical field towards personalized treatment for lung cancer, mesothelioma, breast cancer and other medical conditions. Treatment targeted to a particular patient optimizes the potential for success of the treatment, limits experimental treatments, and also provides the patient with more choices for therapy. Companies focused on research in the identification of biomarkers, a specific biological trait associated with a disease or health condition, are critical to allow physician’s to target their treatment to each patient.
The conference, held in Raleigh, North Carolina February 21-22 is expected to draw over 1,200 industry executives, scientists and entrepreneurs, as well as over 100 investors.